Trial · NCT06584162
Subcutaneous Interval Lengthening of Vedolizumab for Economic Research
NCT06584162, Phase 4, Unknown, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Subcutaneous Interval Lengthening of Vedolizumab for Economic Research. Trials, record NCT06584162. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06584162
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Subcutaneous Interval Lengthening of Vedolizumab for Economic Research
- NCT number
- NCT06584162
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Vedolizumab Injection
- First posted
- 2024-09-04
- Last updated
- 2024-09-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cost-effectiveness | 48 weeks | Medical and societal expenses will be measured troughout the study. The primary outcome is at the end of the study at Week 48. Cost-effectiveness will be measured by using a cost-questionnaire developed with the health economics department, including health-related, work-related and societal costs. |
| Secondary | Difference in Quality of Life | multipe times between baseline and 48 weeks | Quality of life will be measured by EQ-5D-5L questionnaire |
| Secondary | Biochemical parameters | multipe times between baseline and 48 weeks | CRP |
| Secondary | Biochemical parameters | multipe times between baseline and 48 weeks | Fecal calprotectin |
| Secondary | Pharmacokinetic aspects | multipe times between baseline and 48 weeks | Vedolizumab concentrations |
| Secondary | Pharmacokinetic aspects | multipe times between baseline and 48 weeks | Anti-drug antibodies |
| Secondary | Difference in Quality of Life | multipe times between baseline and 48 weeks | Quality of life will be measured by SIBDQ |
| Secondary | Clinical outcomes | multipe times between baseline and 48 weeks | Clinical outcomes will be measured troughout the study. For ulcerative colitis patients: Simple Clinical Colitis Activity Index. |
| Secondary | Clinical outcomes | multipe times between baseline and 48 weeks | Clinical outcomes will be measured troughout the study. For Crohn\'s disease patients: Harvey-Bradshaw Index. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06584162
GET https://conductscience.org/api/trials/v1/NCT06584162/registered